Jeffrey (“jeff”) A. Mattis

Biography

Dr. Mattis is a biopharmaceutical executive with more than 30 years of experience in the development of biopharmaceuticals. In 1979 Dr. Mattis joined Centocor where he served for 18 years, most recently as Vice President of Pharmaceutical Development. While at Centocor, he was instrumental in the technical development of several biopharmaceuticals approved for the U.S. and multinational markets. These include ReoPro®, an anti-platelet drug for use in coronary angioplasty and Remicade®, a drug for treatment of Crohn’s disease and rheumatoid arthritis. After a short period of consulting to emerging biotechnology companies and universities, Dr. Mattis joined Molecular Targeting Technologies, Inc. (MTTI) as Sr. Vice President of Scientific and Regulatory Affairs. MTTI is a privately held biotechnology company primarily focused on the development of small molecules for the molecular imaging of cardiovascular diseases and cancer. MTTI is also developing innovative Zn-DPA technology developed at the University of Notre Dame for the detection anionic cell membranes, a marker of apoptosis.

Research Interest

pharmaceutical